Praetego’s progress is routinely updated as we strive to enter clinical trials.
Please check back frequently for news, announcements, and events.
March 1, 2023
Praetego Inc, a pharmaceutical company protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $0.3M STTR award from the National Eye Institute. The Phase 1 award advances Praetego’s lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.
